HIỆU QUẢ CỦA ĐIỀU TRỊ LÂU DÀI BẰNG HORMON TÁI TỔ HỢP Ở TRẺ THIẾU HỤT HORMON TĂNG TRƯỞNG

Abstract

Growth Hormone Deficiency (GHD) is a common cause of short stature, treated with the standard regimen of subcutaneous synthetic growth hormone (GH). Patients typically achieve a maximum height velocity in the first year of treatment, which then tapers shortly after treatment is stopped. Objective: to describe long-term outcomes of patients with GHD treated with rhGH. Patients and Methods: this is case series study on three patients with growth hormone deficiency aged 47 and 75 months. All patients presented with short sature (< -4 SD for age and sex); basal hormone levels showed low serum IGF1; skeletal wrist age was younger than chronologic age; cranial MRI revealed no masses. In the first case, provocative glucagon -GH stimulation testing demonstrated a peak GH level of 0.024 ng/mL.GH supplementation was started and pursued for 3 – 5  years. Results: dramatically increased height velocity: 14 – 18 cm in the first year, gradually decrease in the following years. Significant catch- up growth occurred in all of them after 3 years. Conclusion: short sature was the main clinical symtom of children on set GHD, in this case series. Early initiation of GH treatment in children with GHD improves their chance of achieving their normal height velocity.